Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Gilead Sciences (United Kingdom), United Kingdom, covering academic research published from 2001 to 2024. Read More.
Open Access Percentage
76%
Total
Publications
254
Total Open
Publications
192
Total
Citations
5.4K
Open Access
Percentage
76%
Total
Publications
254
Total Open
Publications
192
Total
Citations
5.4K
Breakdown
Publisher Open
36%
Both
32%
Other Platform Open
8%
Closed
24%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 35%
61
Hybrid 39%
67
No Guarantees 26%
44
Other Platform Open
Domain 85%
86
Institution 30%
30
Preprint 9%
9
Other Internet 8%
8
Public 3%
3
Other Platform Locations
Name | Platform Type | Publications |
---|---|---|
PubMed Central | Domain | 86 |
Europe PMC | Domain | 31 |
University of Bristol - Bristol Research | Institution | 7 |
University of Dundee - Discovery Research Portal | Institution | 4 |
Research Square | Preprint | 4 |
London School of Hygiene and Tropical Medicine - LSHTM Research Online | Institution | 4 |
University of Oxford - Oxford University Research Archive (ORA) | Institution | 3 |
University of Nottingham - Repository@Nottingham | Institution | 3 |
University of Milano-Bicocca - BOA - Bicocca Open Archive | Institution | 3 |
The University of Glasgow - Enlighten: Publications | Institution | 3 |